27 February 2020
Visiongain has launched a new pharma report Top 25 Vaccines Market Forecast to 2029: Prevnar/Prevnar 13; Gardasil/Gardasil 9; Fluzone/Vaxigrip; Pentacel; Infanrix, Pediarix; GSK Hepatitis Vaccine; Pneumovax 23; Varivax; Bexsero; Boostrix; Menactra; RotaTeq; Rotarix; Zostavax; Synflorix; FluLaval/Fluarix; ProQuad; M-M-R II; Adacel; Menveo; Repevax; Cervarix; FSME/IMMUN-TicoVac; Ixiaro; FluMist/Fluenz.
Visiongain predicts that the overall global market, submarket and product revenues will continue to grow, with human vaccines driving the sales of pharmaceutical companies. The industry will see entry of new key players and advancements in technology, overall resulting in an increase in market size of the world human vaccines market.
The lead analyst of the report commented "There is an increasing focus to identify diseases that currently do not have a vaccine. This breeds a strong platform for both start-ups and larger pharmaceutical companies to create new vaccines that are not already on the market. This prevents stagnation within the market and will help drive the growth of the human vaccines market.
The media is playing an increasingly important role in spreading awareness about the complications of various infectious diseases if the public is not immunized. The increasing levels of awareness has promoted the benefits of vaccines as the most effective form of immunization against infection, consequently leading to increased demand for the vaccines."
Leading companies featured in the report include AstraZeneca, Eli Lilly, Emergent BioSolutions Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Pfizer, Sanofi, Serum Institute of India Private Limited, Takeda and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.
15 September 2022
The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.